LASITA-D

bt_bb_section_bottom_section_coverage_image
https://www.larivinpharma.com/wp-content/uploads/2024/04/LASITA-D-1.jpg

Composition

Dapagliflozin 10 mg & Sitagliptin 50 mg Tablets

Pack: 10 tablets/strip

Dosage:

  • Recommended Dose: One tablet once daily, typically taken in the morning.
  • Special Populations:
    • Renal Impairment: Dose adjustments may be necessary based on kidney function. Consult with a healthcare professional.
    • Hepatic Impairment: Use with caution; monitor liver function regularly.
    • Elderly: Monitor renal function and adjust dosage as needed.

Mode of Action:

  • Dapagliflozin: A sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. It helps in improving glycemic control and has additional benefits in reducing cardiovascular risk and potentially slowing the progression of renal disease.
  • Sitagliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, which in turn increase insulin release and decrease glucagon levels in a glucose-dependent manner. This helps in controlling blood glucose levels without causing significant hypoglycemia when used alone.

Indication:

  • Type 2 diabetes mellitus, to improve glycemic control in adults as part of a combination therapy.

How to Take Lasita-D:

  • Take one tablet daily, preferably at the same time each day for optimal results.
  • Swallow the tablet whole with water, with or without food.
  • Do not crush or chew the tablet.

Possible Side Effects:
As with all medications, Lasita-D may cause side effects, although not everyone will experience them. Common side effects include:

  • Urinary Tract Infections (UTIs): Symptoms may include pain or burning sensation during urination, increased frequency of urination, or cloudy urine.
  • Hypoglycemia (Low Blood Sugar): Particularly when combined with other antidiabetic medications. Symptoms include dizziness, sweating, confusion, and trembling.
  • Gastrointestinal Issues: Nausea, diarrhea, or stomach pain may occur, especially initially.
  • Thirst and Increased Urination: These are common with dapagliflozin due to its mechanism of action.
  • Joint Pain: Some patients may experience joint pain, which can be severe in some cases.
  • Pancreatitis: Rare but serious, symptoms include severe stomach pain, nausea, and vomiting.
  • Dehydration: Due to increased urination, there is a risk of dehydration, which can lead to dizziness or fainting.

Precautions:

  • Renal Function: Regular monitoring is required, especially in patients with existing kidney issues.
  • Pancreatitis Risk: Be aware of the symptoms of pancreatitis and seek medical attention if they occur.
  • Heart Failure: Use with caution in patients with a history of heart failure or other cardiovascular conditions.
  • Volume Depletion: Monitor for signs of dehydration, particularly in elderly patients or those on diuretics.

Consult Your Doctor:

  • Before starting Lasita-D if you have any pre-existing medical conditions, especially related to kidneys, liver, or heart.
  • If you experience any unusual symptoms or side effects, particularly signs of pancreatitis or severe joint pain.
  • For personalized advice on managing your diabetes, including diet and exercise.

Disclaimer:
This information is provided for educational purposes only. For personalized medical advice and treatment options, consult a healthcare professional.

https://www.larivinpharma.com/wp-content/uploads/2020/06/large_blue_triangle_04.png
https://www.larivinpharma.com/wp-content/uploads/2024/04/LASITA-D-1.jpg
https://www.larivinpharma.com/wp-content/uploads/2020/04/small_blue_triangle.png
https://www.larivinpharma.com/wp-content/uploads/2020/06/large_blue_triangle_01.png
https://www.larivinpharma.com/wp-content/uploads/2023/03/larivin-pharma-footer-icon-160x160.png
No.32, First Floor, Varadharaja Swamy Nagar, Sri Krishna Nagar, Maduravoyal, Chennai, Tamil Nadu 600095

© 2023 Larivin Pharma Private Limited. All rights reserved